FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2902628587> ?p ?o ?g. }

• W2902628587 endingPage "e680" @default.
• W2902628587 startingPage "e680" @default.
• W2902628587 abstract "Powerful monoclonal antibodies able to neutralise many HIV-1 circulating viral variants (bnMAbs) are safe and effective, reducing viraemia and delaying viral rebound in patients chronically infected with HIV-1.1Jaworski JP Cahn P Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1.Lancet HIV. 2018; (published online Sept 20.)http://dx.doi.org/10.1016/S2352-3018(18)30174-7Summary Full Text Full Text PDF Scopus (11) Google Scholar However, single-bnMAb therapy does not maintain long-term virus suppression and, similar to what was described during the early days of antiretroviral therapy, resistance to antibodies arises. Combinations of bnMAbs directed to different sites on HIV-1 envelop protein (Env) are needed. Two phase 1b clinical trials have shown that combination bnMAb therapy (with 3BNC117 and 10-1074) targeting different sites on Env effectively suppressed HIV-1 for months. In one of these studies, Mendoza and colleagues2Mendoza P Gruell H Nogueira L et al.Combination therapy with anti-HIV-1 antibodies maintains viral suppression.Nature. 2018; 561: 479-484Crossref PubMed Scopus (276) Google Scholar tested these bnMAbs in 11 people infected with HIV-1 who had suppressed viraemia with antiretroviral drugs. Administered during analytical treatment interruption, three infusions of these antibodies (at 0 weeks, 3 weeks, and 6 weeks) were sufficient to maintain viraemia below detection levels, for more than 15 weeks (mean of 21 weeks), in nine individuals with antibody-sensitive viruses in their reservoirs.2Mendoza P Gruell H Nogueira L et al.Combination therapy with anti-HIV-1 antibodies maintains viral suppression.Nature. 2018; 561: 479-484Crossref PubMed Scopus (276) Google Scholar In the other study, Bar-On and colleagues3Bar-On Y Gruell H Schoofs T et al.Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.Nat Med. 2018; 24: 1701-1707Crossref PubMed Scopus (147) Google Scholar assessed the same bnMAb combination in seven untreated participants with detectable HIV-1. bnMAbs significantly reduced viraemia (2 log10 on average) and limited the emergence of resistant viral variants for an average time-frame of 12 weeks in the four patients who had dual antibody-sensitive viruses.3Bar-On Y Gruell H Schoofs T et al.Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.Nat Med. 2018; 24: 1701-1707Crossref PubMed Scopus (147) Google Scholar If these results can be confirmed in larger numbers of individuals, bnMAbs could simplify treatment for people who are taking daily medication and would reduce the risks of drug resistance and toxic effects. Furthermore, bnMAbs could increase efficacy of antiretroviral therapy by augmenting antiviral immunity4Schoofs T Klein F Braunschweig M et al.HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.Science. 2016; 352: 997-1001Crossref PubMed Scopus (212) Google Scholar and targeting viral reservoirs.5Borducchi EN Liu J Nkolola JP et al.Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys.Nature. 2018; (published online Oct 3.)DOI:10.1038/s41586-018-0600-6Google Scholar I declare no competing interests. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1The viral plasticity and the vast diversity of HIV-1 circulating strains necessitates the identification of new approaches to control this global pandemic. New generation broadly neutralising monoclonal antibodies (bnMAbs) against the HIV-1 viral envelope protein (Env) can prevent virus acquisition, reduce viraemia, enhance immunity, and induce the killing of infected cells in animal models of HIV-1 infection. Most importantly, passively administered bnMAbs are effective at decreasing viraemia and delaying viral rebound in people chronically infected with HIV-1. Full-Text PDF" @default.
• W2902628587 created "2018-12-11" @default.
• W2902628587 creator A5028728919 @default.
• W2902628587 date "2018-12-01" @default.
• W2902628587 modified "2023-10-06" @default.
• W2902628587 title "Long-lasting HIV suppression by combined immunotherapy" @default.
• W2902628587 cites W2346116821 @default.
• W2902628587 cites W2889987866 @default.
• W2902628587 cites W2890205877 @default.
• W2902628587 cites W2892753696 @default.
• W2902628587 cites W2895775323 @default.
• W2902628587 doi "https://doi.org/10.1016/s2352-3018(18)30294-7" @default.
• W2902628587 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30527324" @default.
• W2902628587 hasPublicationYear "2018" @default.
• W2902628587 type Work @default.
• W2902628587 sameAs 2902628587 @default.
• W2902628587 citedByCount "0" @default.
• W2902628587 crossrefType "journal-article" @default.
• W2902628587 hasAuthorship W2902628587A5028728919 @default.
• W2902628587 hasBestOaLocation W29026285871 @default.
• W2902628587 hasConcept C142462285 @default.
• W2902628587 hasConcept C159047783 @default.
• W2902628587 hasConcept C159654299 @default.
• W2902628587 hasConcept C203014093 @default.
• W2902628587 hasConcept C2777701055 @default.
• W2902628587 hasConcept C2993143319 @default.
• W2902628587 hasConcept C3013748606 @default.
• W2902628587 hasConcept C542903549 @default.
• W2902628587 hasConcept C71924100 @default.
• W2902628587 hasConcept C8891405 @default.
• W2902628587 hasConceptScore W2902628587C142462285 @default.
• W2902628587 hasConceptScore W2902628587C159047783 @default.
• W2902628587 hasConceptScore W2902628587C159654299 @default.
• W2902628587 hasConceptScore W2902628587C203014093 @default.
• W2902628587 hasConceptScore W2902628587C2777701055 @default.
• W2902628587 hasConceptScore W2902628587C2993143319 @default.
• W2902628587 hasConceptScore W2902628587C3013748606 @default.
• W2902628587 hasConceptScore W2902628587C542903549 @default.
• W2902628587 hasConceptScore W2902628587C71924100 @default.
• W2902628587 hasConceptScore W2902628587C8891405 @default.
• W2902628587 hasIssue "12" @default.
• W2902628587 hasLocation W29026285871 @default.
• W2902628587 hasLocation W29026285872 @default.
• W2902628587 hasOpenAccess W2902628587 @default.
• W2902628587 hasPrimaryLocation W29026285871 @default.
• W2902628587 hasRelatedWork W1945359667 @default.
• W2902628587 hasRelatedWork W2071428655 @default.
• W2902628587 hasRelatedWork W2140412799 @default.
• W2902628587 hasRelatedWork W2186906753 @default.
• W2902628587 hasRelatedWork W2321454061 @default.
• W2902628587 hasRelatedWork W2408212252 @default.
• W2902628587 hasRelatedWork W2462108502 @default.
• W2902628587 hasRelatedWork W2527791583 @default.
• W2902628587 hasRelatedWork W2912123654 @default.
• W2902628587 hasRelatedWork W2987747606 @default.
• W2902628587 hasVolume "5" @default.
• W2902628587 isParatext "false" @default.
• W2902628587 isRetracted "false" @default.
• W2902628587 magId "2902628587" @default.
• W2902628587 workType "article" @default.